Acylcarnitine Analysis using the Perkin Elmer Neobase Kit. Katherine Wright Alder Hey, Liverpool
|
|
|
- Daniel Montgomery
- 5 years ago
- Views:
Transcription
1 Acylcarnitine Analysis using the Perkin Elmer Neobase Kit Katherine Wright Alder Hey, Liverpool
2 2007 Work on an in-house method for acylcarnitines (Waters, Quattro Micro) However... - Newborn Screening at Alder Hey using PE Kit (Neogram) -? Usage and stability of CIL Acylcarnitine/Amino Acid Internal Standard MCADD Screening introduced July 2008 Full scan analysis required as part of newborn screening follow-up Decision made to develop a diagnostic service for acylcarnitines using the PE non-derivatised Neobase Kit. 1 st July 2009 First diagnostic samples reported on by Alder Hey
3 The Assay Non-Derivastised. Kit contains Internal Standards and QC for : C0, C2, C3, C4, C5, C5DC, C6, C8, C10, C12, C14, C16 and C18 (and amino acids) 1. Reconstitute Internal Standard in Extraction Solution (stable for 30 days). 2. Working solution prepared daily. 3. One 3.2mm bloodspot punch per well ul working solution added (IS and extraction solution). 5. Plate covered and incubated for 45 min at 45 o C with shaking. 6. MS/MS Analysis.
4 Developing the Knowledge Comparisons of numerical data and interpretation with current provider. Collation of in-house population data. CDC quantitative EQA. ERNDIM Interpretative Scheme. Case-based learning exercise. Introduced a tiered approach : Cut-offs for referral based on comparison data and population limits. Results either reported as normal * or sent to external laboratory for analysis. Review of results.
5 An audit 9 months after this service was introduced showed we were only sending away 39% of the samples we had been previously. About half of these were being reported as normal. Post Mortem samples, urine and plasma sent away for analysis. Developments : Introduced use of C3/C2 and C16/C2 ratios. Further ERNDIM Interpretative Samples. Revised population limits. Collection of post-mortem data. A continuing learning curve and adding to knowledge...
6 Positive bias for C5DC : Neobase contains an IS for C5DC. Lessons from EQA Target Neobase Group Alder Hey Also high for Neobase kit QC. Alder Hey Population Range (CDC cut-off 0.35) Potential for over interpretation rather than missing a case.
7 Lessons from EQA Significant positive bias seen for C4-OH (TV= 0.07, Alder Hey = 0.47) : Positive bias only seen for 1 out of 5 samples, and the Neobase group mean was also high. This sample contained C3DC. Isobaric Interference between C4-OH and C3DC. - C4-OH and C3DC share the same m/z ratio of on the non-derivastised assay therefore both contribute to the intensity at The two cannot be distinguished and an elevated level would need to be confirmed using a derivatised assay. Also get isobaric interference between e.g. C4DC in MMA and C5-OH.? high C5 may interfere in C4-OH/C3DC (M+2 isotopic interference)
8 Lessons from EQA Negative Bias for C8 and C10 : Noticeable on CDC but would not have missed MCADD. C8 good on NEQAS although C10 does show negative bias. For Newborn Screening instructed to calibrate C10 with C8 IS. -? Rationale. - Do other labs do this?
9 Lessons from EQA? Concentration dependent bias for C14:1 : Target Value Alder Hey Neobase mean on target at low levels. High level Neobase mean lower.? Issue of sensitivity. Possible false negatives but? in disease.? Drug interference in C14:1.? Low risk of over-interpretation? other acylcarnitines always high in VLCAD.
10 Lessons from EQA Cut-Offs...Significant Limits v. Population Limits : Using population ranges rather than significant limits means Alder Hey cutoffs tend to be lower than CDC and other labs, however in general interpretation agrees with the consensus.? More potential for over interpretation and referral rather than missing a significant finding using population limits rather than significant limits. Cases of carnitine deficiency have also been correctly identified.
11 Population Range C C C C C4-OH C C5: C5DC C5-OH C C6DC C C8: C C10: C10: C C12: Population Range C C14: C14: C14-OH C C16: C16:1-OH C16-OH C C18: C18:1-OH C18: C18-OH C3/C C3/C C8/C C16/C
12 Normal QC Abnormal QC Alder Hey Alder Hey C C C C C C C C C4-OH C4-OH C C C5: C5: C5DC C5DC C5-OH C5-OH C C C6DC C6DC C C C8:1 C8:1 C C C10: C10: C10: C10: C C C12: C12: C C C14: C14: C14: C14: C14-OH C14-OH C C C16: C16: C16:1-OH C16:1-OH C16-OH C16-OH C C C18: C18: C18:1-OH C18:1-OH C18: C18: C18-OH C18-OH
Newborn Screening by Tandem
Newborn Screening by Tandem Mass Spectrometry in Texas Patricia Hunt Manager, Newborn Metabolic Screening Group Biochemistry and Genetics Branch Texas Department of State Health Services May 30, 2012 Texas
Annual Report Zurich 2017 Date of issue: 19 th April 2018 Amended report issued: 1 st May
ERNDIM Administration Office Manchester Centre for Genomic Medicine 6 th Floor, St Mary's Hospital, Oxford Road, Manchester M13 9WL, United Kingdom. Tel: +44 161 276 6741 Fax: +44 161 850 1145 Email: admin@erndim.org
NEWBORN EXPANDED SCREENING NEXT GENERATION. NeoBase 2 Non-derivatized MSMS kit
NEXT GENERATION EXPANDED NEWBORN SCREENING NeoBase Non-derivatized MSMS kit The next generation NeoBase Non-derivatized MSMS kit gives you the ability to screen for all the common amino acid, organic acid
Acylcarnitine measurement in blood spots: methodological aspects, problems and pitfalls with reference to the ERNDIM QA scheme
Acylcarnitine measurement in blood spots: methodological aspects, problems and pitfalls with reference to the ERNDIM QA scheme Charles Turner Laboratory Guy s Hospital (Evelina Childrens Hospital, St Thomas
Mary Seeterlin, PhD Michigan Department of Community Health. Prevent Disease Promote Wellness Improve Quality of Life
Mary Seeterlin, PhD Michigan Department of Community Health Prevent Disease Promote Wellness Improve Quality of Life CPTII - Three Clinical Phenotypes Lethal Neonatal Most severe form Symptoms begin within
Carnitine / Acylcarnitines Dried Blood Spots LC-MS/MS Analysis Kit User Manual
Page 1 / 14 Carnitine / Acylcarnitines Dried Blood Spots LC-MS/MS Analysis Kit User Manual ZV-3051-0200-15 200 Page 2 / 14 Table of Contents 1. INTENDED USE... 3 2. SUMMARY AND EXPLANATION... 3 3. TEST
INTERNAL QUALITY CONTROL ( Q I C) QC)
EXTERNAL QUALITY ASSESSMENT PROGRAM (EQAP) BIOCHEMISTRY DEPARTMENT R. Mohammadi Biochemist (Ph.D.) Faculty member of Medical Faculty TWO COMPLEMENTARY COMPONENETS OF TQM ARE Internal Quality Control (IQC)
HIV Testing and Systems for Managing HIV Implementation in Resource Limited Settings
HIV Testing and Systems for Managing HIV Implementation in Resource Limited Settings Elizabeth M. Dax with the staff of the National Serology Reference Laboratory, Australia My Background Worked in HIV
Practical relevance of measurement uncertainty in inborn errors of metabolism. Prof Jim Bonham Clinical Director Sheffield Children s NHS FT
Practical relevance of measurement uncertainty in inborn errors of metabolism Prof Jim Bonham Clinical Director Sheffield Children s NHS FT Outline Is it important for inborn errors? What is measurement
METABOLIC TEST REPERTOIRE
METABOLIC TEST REPERTOIRE Department of Medical Biochemistry and Immunology University Hospital of Wales Heath Park Cardiff CF14 4XW Metabolic section open Monday to Friday 08:45 to 17:15 For Laboratory
Neonatal Screening using Shimadzu LCMS-8040
PO-CON1355E Neonatal Screening using Shimadzu LCMS-8040 HPLC 2013 BIOM-31 Stefano Zaza 1 ; G. La Marca 2 ; S.Malvagia 2 1 Shimadzu Italy, Milano, Italy 2 Mass Spectrometry and Pharmacology Laboratory,
Annual Report on the External Quality Assessment Scheme for Biochemical Genetics in Korea (2014)
ANNUAL REPORT http://dx.doi.org/10.15263/jlmqa.2015.37.2.56 Annual Report on the External Quality Assessment Scheme for Biochemical Genetics in Korea (2014) Soo-Youn Lee 1, Ok Ja Ji 1, Gye Cheol Kwon 2,
Xiaolei Xie, Marta Kozak. Thermo Fisher Scientific, 355 River Oaks Parkway, San Jose, CA Introduction
Comparison of Non-derivatization and Derivatization Tandem Mass Spectrometry Methods for Analysis of Amino Acids, Acylcarnitines, and Succinylacetone in Dried Blood Spots Xiaolei Xie, Marta Kozak Thermo
Neonatal Screening using Shimadzu LCMS- 8040
SEG- 2050 Application Note for The Analytical Scientist 11-13 Neonatal Screening using Shimadzu LCMS- 8040 Introduction The development of electrospray tandem mass spectrometry (LCMS/MS) in recent years
MS/MS APPROACHES TO CLINICAL TESTING FOR INBORN ERRORS OF METABOLISM
MS/MS APPROACHES TO CLINICAL TESTING FOR INBORN ERRORS OF METABOLISM Tina M. Cowan, PhD Director, Clinical Biochemical Genetics Laboratory Stanford University Medical Center Presented at the 2011 Stanford
A Laboratory Guide to Newborn Screening in the UK for
A Laboratory Guide to Newborn Screening in the UK for MEDIUM-CHAIN ACYL-CoA DEHYDROGENASE DEFICIENCY UK Newborn Screening Programme Centre www.newbornbloodspot.screening.nhs.uk A Laboratory Guide to Newborn
LSD EASY AND EFFICIENT SCREENING. NeoLSD MSMS kit
EASY AND EFFICIENT LSD NeoLSD MSMS kit The first commercial IVD kit for screening of Pompe, MPS-I, Fabry, Gaucher, Niemann-Pick A/B and Krabbe disorders from a single DBS sample. A PIONEER IN EXPANDING
Simultaneous Analysis of Amino Acids and Acylcarnitines in Dried Blood Spots
Simultaneous Analysis of Amino Acids and Acylcarnitines in Dried Blood Spots Application Note Authors M.P. George Alere Toxicology Services Gretna, LA USA David Presser Agilent Technologies, Inc Santa
Biochemical Genetics
Biochemical Genetics Laboratory Handbook 20010/11 Block 20 St James s Hospital Beckett Street Leeds LS9 7TF Introduction The Biochemical Genetics service is comprised of two regional laboratories, screening
Amino Acid Methods: Present and Future. Claire Hart Sheffield Children s Hospital
Amino Acid Methods: Present and Future Claire Hart Sheffield Children s Hospital The Status Quo Questionnaire shows everybody using HPLC or ion-exchange amino acid analysers for routine quantitative services
Molecular blood spot performance monitoring
Molecular blood spot performance monitoring Description This management procedure document details the processes involved in determining the performance standard of each participating laboratory in the
Title: Assessing Recommendations Related To Timeliness of Newborn Screening
Title: Assessing Recommendations Related To Timeliness of Newborn Screening Purpose: In January 2014, the Secretary s Discretionary Advisory Committee on Heritable Diseases on Newborns and Children (Committee)
Newborn Screening & Methods for Diagnosing Inborn Errors of Metabolism
Newborn Screening & Methods for Diagnosing Inborn Errors of Metabolism Patricia Jones, PhD DABCC FACB UT Southwestern Medical Center Children s Medical Center Dallas, Texas Learning Objectives Justify
Cortisol Assays. The Good, The Bad and The Indifferent. David Ducroq. Cardiff and Vale ulhb WEQAS. Unit 6, Parc Tŷ Glas. Llanishen.
Cortisol Assays The Good, The Bad and The Indifferent David Ducroq Cardiff and Vale ulhb WEQAS Unit 6, Parc Tŷ Glas Llanishen Cardiff www.weqas.com Summary Brief overview of current methods and challenges
The challenges of quality assessment for point-of-care testing. Anne Stavelin. EQALM Symposium, Bergen 8 October General challenges
The challenges of quality assessment for point-of-care testing Anne Stavelin EQALM Symposium, Bergen 8 October 2015 www.noklus.no Norwegian quality improvement of primary care laboratories General challenges
Mass Spectrometry Made Simple for Clinical Diagnostic Labs
Mass Spectrometry Made Simple for Clinical Diagnostic Labs The SCIEX Topaz System with FDA-Cleared Topaz Vitamin D 200M Assay Kit Mass Spectrometry Made Simple SCIEX Topaz System for Clinical Diagnostics
Prior to site activation the following events were lined up
Pardon Gomani CALENDAR OF EVENTS Prior to site activation the following events were lined up October 2008 Operational walk through in JHB 9 to 17 July study specific training Harare 27 August 09 site specific
Adenosine deaminase severe combined immunodeficiency (ADA-SCID)
Adenosine deaminase severe combined immunodeficiency (ADA-SCID) Christopher A. Haynes, PhD Service Fellow, CDC National Conversation: Tandem Mass Spectrometry in Newborn Screening February 5-6, 2015 National
An Evolution of Michigan s SCID Algorithm
An Evolution of Michigan s SCID Algorithm A qualitative approach for the T cell receptor excision circle (TREC) assay for the detection of primary immune deficiency syndromes (PIDS) demonstrates better
Disclosures. Relevant Financial Relationship(s): Nothing to Disclose. Off Label Usage: Nothing to Disclose 9/19/2017. Proficiency Testing
September 11, 2017 Teri Ross, Quality Specialist II Doreen Ryan, MA, MT; Quality Operations Supervisor Deborah J. Wells, MPA, MT(ASCP)SH, Quality Management Coordinator Disclosures Relevant Financial Relationship(s):
Connecticut Newborn Screening For X- Linked Adrenoleukodystrophy
Connecticut Newborn Screening For X- Linked Adrenoleukodystrophy Adrienne Manning, Division Director, Newborn Screening Connecticut Department of Public Health Katherine A. Kelley Public Health Laboratory
Alkaline Phosphatase Assay Kit
Alkaline Phosphatase Assay Kit Catalog Number KA0817 500 assays Version: 02 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Background... 3 General Information... 4 Materials
Connecticut Newborn Screening For X-Linked Adrenoleukodystrophy
Connecticut Newborn Screening For X-Linked Adrenoleukodystrophy Adrienne Manning, Division Director, Newborn Screening Connecticut Department of Public Health Katherine A. Kelley Public Health Laboratory
CDC Laboratory Support
Newborn Bloodspot Screening for Severe Combined Immune Deficiency (NBS-SCID) CDC Laboratory Support APHL Webcast Robert F. Vogt, Jr., Ph.D. Research Chemist Newborn Screening and Molecular Biology Branch
Recommended Additional EUA QC checks for Zika MAC-ELISA. Wendi Kuhnert, PhD Co-Lead, Zika Laboratory Task Force
Recommended Additional EUA QC checks for Zika MAC-ELISA Wendi Kuhnert, PhD Co-Lead, Zika Laboratory Task Force Current Plans 3 Phase approach to standardize the Zika MAC-ELISA Phase 1: Distribution of
Short Term Follow Up Tandem Mass Spectrometry Workshop Agenda
Short Term Follow Up Tandem Mass Spectrometry Workshop Agenda June 11-15, 2018 APHL Headquarters 8515 Georgia Ave Silver Spring, MD 20910 This meeting is sponsored by the Association of Public Health Laboratories
Information for health professionals
Changes to the Newborn Bloodspot Screening Policy for Congenital Hypothyroidism (CHT) in Preterm Babies A UK policy change has been agreed that will mean changes to: which preterm babies require second
ERNDIM update. Dr Mick Henderson. Chairman Executive Committee
ERNDIM update Dr Mick Henderson Chairman Executive Committee Summary of Current Profile Quantitative Amino Acids Quantitative Organic Acids Qualitative Organic Acids Special Metabolic Assays Purines and
Implementation of Newborn Screening for Duchenne Muscular Dystrophy.
Implementation of Newborn Screening for Duchenne Muscular Dystrophy. Michele A. Lloyd-Puryear, MD, PhD 1, Stuart J Moat, PhD 2, Amy Brower 3, PhD, Annie Kennedy 1, Petra Furu 4, Michael Watson, PhD 3,
Summary of Significant Changes at this Revision. Items Required. Printed copies are uncontrolled unless there is an allocated Copy Number on page 1
COPY Summary of Significant Changes at this Revision 1. Change author from M Stubberfield to N Hodges Purpose and Scope Items Required The One Step Pregnancy Test urine test strip is a rapid chromatographic
What Makes a Satisfactory Newborn Screen Sample?
What Makes a Satisfactory Newborn Screen Sample? Feb 21, 2013 Christine McRoberts Newborn Screening Ontario One of the challenges the Newborn screening Ontario program (NSO) faces every day is the receipt
Quantitative Analysis of Vit D Metabolites in Human Plasma using Exactive System
Quantitative Analysis of Vit D Metabolites in Human Plasma using Exactive System Marta Kozak Clinical Research Applications Group Thermo Fisher Scientific San Jose CA Clinical Research use only, Not for
What I will talk about
EQA of POCT methods: How to interpret results? Anne Stavelin Labquality Days, Helsinki 12 February 2016 www.noklus.no Norwegian quality improvement of primary care laboratories What I will talk about What
Point of Care Testing for INR using CoaguChek XS Plus
Point of Care Testing, Pathology Page 1 of 18 Point of Care Testing for INR using CoaguChek XS Plus EDITION No 1.4 DATE OF ISSUE Feb 2014 REVIEW INTERVAL AUTHOR LOCATION OF COPIES 3 YEARS D O Neill 1.
Lab Guide 2019 Metabolic Section Lab Guide
Lab Guide 2019 Metabolic Section Lab Guide Quantitative Amino acids Plasma Plasma. Container/Tube: Preferred EDTA, Place immediately in ice. Acceptable: lithium heparin, sodium heparin. Patient preparation:
RayBio Acid Phosphatase Activity Colorimetric Assay. Kit. User Manual Version 1.0 May 5, RayBiotech, Inc. Kit Protocol. (Cat#: 68CL-AcPh-S500)
RayBio Acid Phosphatase Activity Colorimetric Assay Kit User Manual Version 1.0 May 5, 2014 RayBio Acid Phosphatase Activity Colorimetric Assay (Cat#: 68CL-AcPh-S500) RayBiotech, Inc. We Provide You With
Use of a Tandem Mass Spectrometry Research Method for the Analysis of Amino Acids and Acylcarnitines in Dried Blood Spots
Use of a Tandem Mass Spectrometry Research Method for the Analysis of Amino Acids and Acylcarnitines in Dried Blood Spots Xiaolei Xie and Marta Kozak Thermo Fisher Scientific, San Jose, CA, USA Application
SUMMARY THE RELEVANCE OF THE NEONATAL URINE SCREENING FOR INBORN ERRORS OF METABOLISM PERFORMED IN QUÉBEC. Introduction
SUMMARY THE RELEVANCE OF THE NEONATAL URINE SCREENING FOR INBORN ERRORS OF METABOLISM PERFORMED IN QUÉBEC Introduction Screening newborns for a number of hereditary diseases is common practice throughout
A Pilot Study on an Expanded Newborn Screening Program in Palestine. Phaseп
A Pilot Study on an Expanded Newborn Screening Program in Palestine. Phaseп Genetics and Metabolic Diseases Center Faculty of Medicine/Al-Quds University Samir Khatib, PhD Amer Ayyad,MSc Outline 1- Background
Medium-chain acyl-coa dehydrogenase deficiency
Medium-chain acyl-coa dehydrogenase deficiency Introductory information Written by: V. Prietsch & P. Burgard Reviewed & Revised for North America by: S. van Calcar Medium-chain acyl-coa dehydrogenase MCAD
2014 Continuing Compliance Master Series Best Practices in Alternative Assessment of Performance
2014 Continuing Compliance Master Series Best Practices in Alternative Assessment of Performance Brad S. Karon, MD, PhD, FCAP November 19, 2014 www.cap.org Today s Presenter Brad S. Karon, MD, PhD, FCAP
National Metabolic Biochemistry Network (MetBioNet) Minutes of Stakeholder Meeting Friday 27 th April 2018, Birmingham Children s Hospital
National Metabolic Biochemistry Network (MetBioNet) Minutes of Stakeholder Meeting Friday 27 th April 2018, Birmingham Children s Hospital Present: Helena Kemp (HK) Bristol, Southmead (Chair) Claire Hart
2017 Newborn Screening and Genetic Testing Symposium September 10, 2017
Removing Short-chain Acyl-CoA Dehydrogenase (SCAD) Deficiency and Isobutyryl-CoA Dehydrogenase Deficiency (IBD) from the Newborn Screening Panel: Michigan s Experience 2017 Newborn Screening and Genetic
SCIEX Vitamin D 200M Assay for the Topaz System
The First FDA-Cleared LC-MS/MS Assay for Vitamin D SCIEX Vitamin D 200M Assay for the Topaz System The first FDA-cleared LC-MS/MS assay for Vitamin D Vitamin D is an important building block for human
The Compelling Benefits of Routine 2 nd NBS: A Fifteen-Year Review in Washington State. Saving lives with a simple blood spot
The Compelling Benefits of Routine 2 nd NBS: A Fifteen-Year Review in Washington State Caroline T. Nucup-Villaruz, MD Primary Author NBS Consultant - Disorder FU Santosh Shaunak Co-Author & Presenter Laboratory
The Many Lives of the Newborn Screening Dried Blood Spot (the LIFE CYCLE of a Blood Spot)
The Many Lives of the Newborn Screening Dried Blood Spot (the LIFE CYCLE of a Blood Spot) Piero Rinaldo, MD, PhD Professor of Laboratory Medicine T. Denny Sanford Professor of Pediatrics Mayo Clinic College
Analytes, instrumentation and software for neonatal screening. Complete solutions for screening newborns
Analytes, instrumentation and software for neonatal screening Complete solutions for screening newborns w w w. p e r k i n e l m e r. c o m 1 Everything you need for efficient neonatal screening PerkinElmer
UK Newborn Screening for X-ALD - progress from a lab perspective
UK Newborn Screening for X-ALD - progress from a lab perspective Mrs. Leila Cornes Senior Clinical Scientist, Newborn Screening Southmead Hospital, Bristol May 2016 C26:0-lysoPC C26:0-lysophosphatidylcholine
Aspects of quality in breast pathology. Andrew Lee Nottingham University Hospitals
Aspects of quality in breast pathology Andrew Lee Nottingham University Hospitals British breast pathology EQA: performance issues Ian Ellis Friday 8.30 am National breast screening pathology audit 2015
An Introduction to the Use of itraq Reagents for Amino Acid Analysis
An Introduction to the Use of itraq Reagents for Amino Acid Analysis Lisa Sapp Clinical Research and Forensic Toxicology Product Manager Mass Spectrometry Systems Amino Acid Analysis Using itraq Reagents
Internal Quality Control in the Haemostasis laboratory. Dr Steve Kitchen Sheffield Haemophilia and Thrombosis centre & UK NEQAS Blood Coagulation
Internal Quality Control in the Haemostasis laboratory Dr Steve Kitchen Sheffield Haemophilia and Thrombosis centre & UK NEQAS Blood Coagulation Why do we need Quality control? Philadelphia Enquirer Aug
ERNDIM QA Scheme for qualitative blood spot acylcarnitine analysis. Annual Report 2010
UniversitätsKlinikum Heidelberg Universitätsklinik für Kinder- und Jugendmedizin Stoffwechselzentrum Heidelberg Stoffwechsellabor Im Neuenheimer Feld 430 69120 Heidelberg To Stoffwechselzentrum Heidelberg
Newborn Bloodspot Screening Information for parents
Newborn Bloodspot Screening Information for parents You will be offered a bloodspot screening test for your newborn baby for several rare but serious conditions. The sample for this test is usually taken
The setup and validation of an LC-MS/MS assay of Androstenedione & Testosterone a labs experience
The setup and validation of an LC-MS/MS assay of Androstenedione & Testosterone a labs experience Keith Mulready Specialist Senior Medical Scientist Why measure Testosterone? Hypogonadism in Males Cancer
Analysis of Testosterone, Androstenedione, and Dehydroepiandrosterone Sulfate in Serum for Clinical Research
Analysis of Testosterone, Androstenedione, and Dehydroepiandrosterone Sulfate in Serum for Clinical Research Dominic Foley, Michelle Wills, and Lisa Calton Waters Corporation, Wilmslow, UK APPLICATION
Newborn Bloodspot Screening Information for parents
Newborn Bloodspot Screening Information for parents You will be offered a bloodspot screening test for your newborn baby for several rare but serious conditions. The sample for this test is usually taken
Newborn Bloodspot Screening (NBS) Training for Health Visitors. December 2017
Newborn Bloodspot Screening (NBS) Training for Health Visitors www.newbornbloodspotscreening.wales.nhs.uk December 2017 Aims To enable you to gain a clear understanding of the following: Aim and rationale
Analysis of drugs of abuse in biological matrix using Time of Flight technology
Analysis of drugs of abuse in biological matrix using Time of Flight technology Niclas Stephanson, PhD Department of Clinical Pharmacology Karolinska University Hospital Karolinska Institutet Stockholm,
A rough guide to Acylcarnitines
A rough guide to Acylcarnitines Roy Talbot & Nigel Manning Roy.Talbot@sch.nhs.uk Dept. of Clinical Chemistry, Sheffield Children s Hospital Menu Acylcarnitines Basic Tandem MS theory SCADD MCADD LCHADD
It is a requirement of ISO that laboratories shall determine the uncertainty of measurement of results, where relevant and possible. (5.6.
Guideline Subject: Uncertainty of Measurement Approval Date: November 2004, November 2009 Review Date: November 2013 Review By: PPAC Number: 2/2004 Introduction This Guideline has been developed to provide
Simple Method (IS-MRM) to Monitor Lysophospholipids and Phospholipids During LC-MS Method Development via In-Source CID
Simple Method (IS-MRM) to Monitor Lysophospholipids and Phospholipids During LC-MS Method Development via In-Source CID James Little, Eastman Chemical Company, Kingsport, TN Overview Phospholipids and
Evaluation of the LIAISON 25 OH Vitamin D TOTAL Assay on the new LIAISON XL analyser
Evaluation of the LIAISON 25 OH Vitamin D TOTAL Assay on the new LIAISON XL analyser Prof. Etienne Cavalier Department of Clinical Chemistry University of Liège, CHU Sart-Tilman Liège, Belgium etienne.cavalier@chu.ulg.ac.be
Alkaline Phosphatase Assay Kit (Fluorometric)
Alkaline Phosphatase Assay Kit (Fluorometric) Catalog Number KA0820 500 assays Version: 02 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Background... 3 General Information...
Point of care, near patient testing, of blood borne viruses issues with design and implementation of programs
Point of care, near patient testing, of blood borne viruses issues with design and implementation of programs Philip Cunningham Conjoint Associate Professor (UNSW) NSW State Reference Laboratory for HIV
Alvaro Serrano Russi MD University of Iowa Hospitals and Clinics
Retrospective Analysis of the Region 4 Post Analytical Tool and Confirmatory Testing for Long Chain Fatty Acid Oxidation Disorders Screened in the State of Iowa Alvaro Serrano Russi MD University of Iowa
Newborn screening for additional metabolic diseases using second-tier strategies Juergen G. Okun, PhD
Newborn screening for additional metabolic diseases using second-tier strategies Juergen G. Okun, PhD 5th EFLM-UEMS European Joint Congress in Laboratory Medicine 10-13 October 2018 in Antalya, Turkey
Vitamin D Metabolite Analysis in Biological Samples Using Agilent Captiva EMR Lipid
Vitamin D Metabolite Analysis in Biological Samples Using Agilent Captiva EMR Lipid Application Note Clinical Research Authors Derick Lucas and Limian Zhao Agilent Technologies, Inc. Abstract Lipids from
Post mortem investigation of Inherited Metabolic Disease - the last opportunity for a diagnosis -
Post mortem investigation of Inherited Metabolic Disease - the last opportunity for a diagnosis - Dr Simon Olpin Lead Clinical Scientist in Inherited Metabolic Disease Sheffield Children s Hospital SIDS/SUDI
Inborn Errors of Metabolism Clinical Approach to Diagnosis and Treatment
Case Scenario: 15 year old girl presented in ED with aggressive behaviour and hallucinations. No associated fever, vomiting, seizures or developmental concerns Previously well Inborn Errors of Metabolism
ANNUAL REPORT In 2007 Nijmegen/Amsterdam DPT-scheme had 19 participants from Belgium, Germany and The Netherlands.
ERNDIM Diagnostic Proficiency Testing Centre Central Europe Nijmegen / Amsterdam Prof. dr. J.L. Willems University Medical Centre Nijmegen SKML, Section Metabolic Diseases P.O. Box 9101 NL 6500 HB Nijmegen
A look across the border
A look across the border Dr. Jim Bonham PNS-congres 17 april 2018 Disclosure I have no disclosures of commercial support. Professionally, I am a member of the Executive Committee of ISNS 2 PNS-congres
Extraction of 25-hydroxy Vitamin D from Serum Using ISOLUTE. PLD+ Prior to LC-MS/MS Analysis
Application Note AN842.V. Extraction of 25-hydroxy Vitamin D from Serum Using ISOLUTE PLD+ Prior to LC-MS/MS Analysis Page Extraction of 25-hydroxy Vitamin D from Serum Using ISOLUTE PLD+ Prior to LC-MS/MS
Use of Derivatization for LC- MS/MS Analysis in the Clinical Lab
Use of Derivatization for LC- MS/MS Analysis in the Clinical Lab Asian Pacific Conference on Chromatography & Mass Spectrometry 2010 15 January 2010 Alan L. Rockwood and Mark M. Kushnir ARUP Laboratories,
PKU (Phenylketonuria) Serum LC-MS/MS Analysis Kit User Manual
Page 1 / 24 PKU (Phenylketonuria) Serum LC-MS/MS Analysis Kit User Manual ZV-3003-0200-10 200 2-8 C Page 2 / 24 Table of Contents 1. INTENDED USE... 3 2. SUMMARY AND EXPLANATION... 3 3. TEST PRINCIPLE...
Measurand characteristics & reference materials for hcg
Measurand characteristics & reference materials for hcg Dr Cathie Sturgeon on behalf of the IFCC Working Group for hcg C/o Department of Clinical Biochemistry Royal Infirmary of Edinburgh C.Sturgeon@ed.ac.uk
Quantitation by High Resolution Mass Spectrometry: Case Study of TOF MS for the Quantitation of Allopurinol from Human Plasma
Quantitation by High Resolution Mass Spectrometry: Case Study of TOF MS for the Quantitation of Allopurinol from Human Plasma Shaokun Pang 1, Weixing Sun 2, Adrien Musuku 2, Xavier J. Misonne 1 1 SCIEX,
HA Convention 2016 Master course How to Handle Abnormal Newborn Metabolic Screening Results Causes, Management and Follow up
HA Convention 2016 Master course How to Handle Abnormal Newborn Metabolic Screening Results Causes, Management and Follow up Dr. Josephine Chong Clinical Professional Consultant Centre of Inborn Errors
A Novel Platform of On-line Sample Pre-treatment and LC/MS/MS Analysis for Screening and Quantitation of Illicit Drugs in Urine
PO-CON737E A Novel Platform of On-line Sample Pre-treatment and LC/MS/MS Analysis for Screening and Quantitation of Illicit Drugs in Urine ASMS 7 WP 353 Shao Hua Chia ; Zhi Wei Edwin Ting ; Daisuke Kawakami
National Quality Assurance Advisory Panel - Genetics
National Quality Assurance Advisory Panel - Genetics Annual Report 2015-16 Meetings The Panel met twice during this period (30th March 2015 and 5th October 2015) with this frequency of meetings set to
Accuracy of Point-of-Care Ultrasonography for Pediatric Ankle Sprain Injuries
Accuracy of Point-of-Care Ultrasonography for Pediatric Ankle Sprain Injuries S Jones 1, K Colaco 2, J Fischer 2, J Stimec 2, C Kwan 2, K Boutis 2 1 Alder Hey Children s NHS Foundation Trust, Prescot Rd,
Manual. Transfer step. Figure 1. Workflow comparison of manual phenylalanine assay and automated GSP Neonatal Phenylalanine assay
TECHNICAL NOTE GSP Neonatal Phenylalanine kit 3308-0010/3308-001B GSP Neonatal Phenylalanine kit (3308-0010/3308-001B) is a fully Introduction automated enzymatic assay for the GSP system. Optimized for
Implementation of High Risk Human Papilloma Virus (Hr-HPV) Primary Testing
Implementation of High Risk Human Papilloma Virus (Hr-HPV) Primary Testing Background In Nov 2015 following a review of evidence the UK National Screening Committee made a recommendation to the UK countries
Attachment 1. Newborn Screening Program Description
Attachment 1 Newborn Screening Program Description The core mission of Texas Newborn Screening Program is to save children s lives through the early detection of life-threatening disorders. 34 Newborn
Quality Corner: Inspection Preparation By Rhonda Burgard, Client Services Supervisor
Volume 12 Issue 59 401 North 9 th Street, Bismarck ND 58501-4507 June 2016 Quality Corner: Inspection Preparation To prepare for a laboratory inspection begin by obtaining the appropriate inspection checklist
Inborn Errors of Metabolism. Metabolic Pathway. Digestion and Fasting. How is Expanded Newborn Screening Different? MS/MS. The body is a factory.
Inborn Errors of Metabolism The body is a factory. Inborn errors of metabolism are rare genetic disorders in which the body cannot properly turn food into energy. The disorders are usually caused by defects
QA/QC 2 Strategies to Reduce False Positives and False Negatives (Part 2)
QA/QC 2 Strategies to Reduce False Positives and False Negatives (Part 2) Tuesday, Oct. 28 10:30am-12:00pm Moderators Patricia Hunt, Texas Department of State Health Services and Bob Currier, California
Validation Report for the Neogen Fentanyl Kit for ELISA Screening of Whole Blood and Urine Specimens
Validation Report for the Neogen Fentanyl Kit for ELISA Screening of Whole Blood and Urine Specimens This document describes the validation of a Neogen Fentanyl kit for the semi-quantitative analysis of
National Quality Assurance Advisory Panel - Genetics
National Quality Assurance Advisory Panel - Genetics Annual Report 2011-12 Meetings The Panel met twice during this period (18th October 2011 and 26 th March 2012) with this frequency of meetings to continue
EpiQuik Circulating Acetyl Histone H3K18 ELISA Kit (Colorimetric)
EpiQuik Circulating Acetyl Histone H3K18 ELISA Kit (Colorimetric) Base Catalog # PLEASE READ THIS ENTIRE USER GUIDE BEFORE USE Uses: The EpiQuik Circulating Acetyl Histone H3K18 ELISA Kit (Colorimetric)
Annual Report ERNDIM-EQAS Quantitative Amino Acids 2004
Annual Report ERNDIM-EQAS Quantitative Amino Acids 2004 1. Purpose The purpose of the ERNDIM External Quality Assurance Scheme for Quantitative Organic Acids is the monitoring of the analytical quality